Duration of protection of pentavalent rotavirus vaccination in Nicaragua

Pediatrics

Volumn 130, Issue 2, 2012, Pages

  Patel, Manish ^a   Pedreira, Cristina ^b   De Oliveira, Lucia Helena ^c   Umaña, Jazmina ^d   Tate, Jacqueline ^a   Lopman, Ben ^a   Sanchez, Edmundo ^e   Reyes, Martha ^d   Mercado, Juan ^d   Gonzalez, Alcides ^d   Perez, Maria Celina ^d   Balmaceda, Angel ^d   Andrus, Jon ^c   Parashar, Umesh ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b PAN AMERICAN HEALTH ORGANIZATION   (Nicaragua)

^c Ministerio de Salud   (Nicaragua)

^d PAN AMERICAN HEALTH ORGANIZATION   (United States)

^e NONE

Author keywords

Diarrhea; Rotavirus; Vaccine; Vaccine effectiveness

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE;

AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; INFECTIOUS DIARRHEA; MAJOR CLINICAL STUDY; MALE; NICARAGUA; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ROTAVIRUS INFECTION; SOCIOECONOMICS; VACCINATION;

ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; DEVELOPING COUNTRIES; DIARRHEA, INFANTILE; FEMALE; HOSPITALIZATION; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; NICARAGUA; ODDS RATIO; POPULATION SURVEILLANCE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TREATMENT OUTCOME; VACCINES, ATTENUATED;

EID: 84864498176     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-3478     Document Type: Article

References (23)

1. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Wkly Epidemiol Rec. 2009;84(23):220-236
2. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA. 2009;301(21):2243-2251
3. de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ. 2010;340:c2825
4. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606-614
5. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):615-623
6. Bresee JS, Hummelman E, Nelson EA, Glass RI. Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines. J Infect Dis. 2005;192(suppl 1):S1-S5 (Pubitemid 41193095)
7. Phillips G, Lopman B, Tam CC, Iturriza-Gomara M, Brown D, Gray J. Diagnosing rotavirus A associated IID: using ELISA to identify a cut-off for real time RT-PCR. J Clin Virol. 2009;44(3):242-245
8. Staat MA, Payne DC, Donauer S, et al New Vaccine Surveillance Network (NVSN). Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics. 2011;128(2). Available at: www.pediatrics.org/cgi/content/full/128/ 2/e267
9. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics. 2010;125(2). Available at: www.pediatrics.org/cgi/content/full/125/2/e199
10. Boom JA, Tate JE, Sahni LC, et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J. 2010;29(12):1133-1135
11. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis. 2010;201(3):363-369
12. Schlesselman JJ. Sample size requirements in cohort and case-control studies of disease. Am J Epidemiol. 1974;99(6):381-384
13. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990;22(3):259-267
14. Vesikari T, Matson DO, Dennehy P, et al Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33 (Pubitemid 43048948)
15. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: Wiley; 2000
16. Amador JJ, Vasquez J, Orozco M, et al. Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program. Int J Infect Dis. 2010;14(7):e592-e595
17. Orozco M, Vasquez J, Pedreira C, et al. Uptake of rotavirus vaccine and national trends of acute gastroenteritis among children in Nicaragua. J Infect Dis. 2009;200(suppl 1):S125-S130
18. Amador JJ, Vicari A, Turcios-Ruiz RM, et al. Outbreak of rotavirus gastroenteritis with high mortality, Nicaragua, 2005. Rev Panam Salud Publica. 2008;23(4):277-284
19. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med. 2010;362(4):299-305
20. Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J. 2010;29(10):957-963
21. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis. 2009;200(suppl 1):S39-S48
22. Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med. 2011;365(8):772-773
23. do Carmo GM, Yen C, Cortes J, et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 2011;8(4):e1001024